Dabigatran versus Warfarin in Patients with Atrial Fibrillation.

Connolly, Stuart; Ezekowitz, Michael; Yusuf, Salim; Eikelboom, John; Oldgren, Jonas; Parekh, Amit; Pogue, Janice; Reilly, Paul; Themeles, Ellison; Varrone, Jeanne; Wang, Susan; Alings, Marco; Xavier, Denis; Zhu, Jun; Diaz, Rafael; Lewis, Basil; Darius, Harald; Diener, Hans-Christoph; Joyner, Campbell; Wallentin, Lars

doi:10.1056/nejmoa0905561

Dabigatran versus Warfarin in Patients with Atrial Fibrillation.

Connolly S. J., Ezekowitz M. D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., ...Daha Fazla

NEW ENGLAND JOURNAL OF MEDICINE, cilt.361, sa.12, ss.1139-1151, 2009 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 361 Sayı: 12
Basım Tarihi: 2009
Doi Numarası: 10.1056/nejmoa0905561
Dergi Adı: NEW ENGLAND JOURNAL OF MEDICINE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1139-1151
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Ankara Üniversitesi Adresli: Hayır

Özet

Background: Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor.